Paul P. Wang

Seaside Therapeutics LLC engages in the development of drug treatments to correct or improve the course of autism, fragile X syndrome and other neurodevelopmental disorders. Its products include STX209, STX107, and STX110. The company was founded by Randall L. Carpenter and Mark F. Bear in 2005 and is headquartered in Cambridge, MA.

Seaside Therapeutics LLC engages in the development of drug treatments to correct or improve the course of autism, fragile X syndrome and other neurodevelopmental disorders. Its products include STX209, STX107, and STX110. The company was founded by Randall L. Carpenter and Mark F. Bear in 2005 and is headquartered in Cambridge, MA.

Seaside Therapeutics LLC engages in the development of drug treatments to correct or improve the course of autism, fragile X syndrome and other neurodevelopmental disorders. Its products include STX209, STX107, and STX110. The company was founded by Randall L. Carpenter and Mark F. Bear in 2005 and is headquartered in Cambridge, MA.

Seaside Therapeutics LLC engages in the development of drug treatments to correct or improve the course of autism, fragile X syndrome and other neurodevelopmental disorders. Its products include STX209, STX107, and STX110. The company was founded by Randall L. Carpenter and Mark F. Bear in 2005 and is headquartered in Cambridge, MA.

Seaside Therapeutics LLC engages in the development of drug treatments to correct or improve the course of autism, fragile X syndrome and other neurodevelopmental disorders. Its products include STX209, STX107, and STX110. The company was founded by Randall L. Carpenter and Mark F. Bear in 2005 and is headquartered in Cambridge, MA.